title: Risk of stent thrombosis after sirolimus or paclitaxel eluting coronary stent implantation.
authors.forename: Raul
authors.initials: R
authors.lastname: Moreno
authors.forename: Cristina
authors.initials: C
authors.lastname: Fernandez
authors.forename: Angel
authors.initials: A
authors.lastname: Sanchez-Recalde
authors.forename: Luis
authors.initials: L
authors.lastname: Calvo
authors.forename: Guillermo
authors.initials: G
authors.lastname: Galeote
authors.forename: Rosa
authors.initials: R
authors.lastname: Sanchez-Aquino
authors.forename: Jose-Luis
authors.initials: JL
authors.lastname: Lopez-Sendon
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003328:Coronary Thrombosis; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*; D012307:Risk Factors; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents
chemical_list: D000900:Anti-Bacterial Agents; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D020123:Sirolimus